ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/XPO1
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/XPO1
8
trial(s) found.
NCT06158841
Haem
Phase 3
Recruiting
A Phase 3, Multicenter, Randomized, Open Label Study of Etentamig Compared With Standard Available Therapies in Subjects With Relapsed or Refractory Multiple Myeloma (3L+ RRMM Monotherapy Study) (
CERVINO
)
ABBV-383
Bortezomib
Carfilzomib
Dexamethasone
Elotuzumab
Pomalidomide
Selinexor
XPO1 inhibitor
anti-CS1 monoclonal antibody
bispecific T-cell engager,BCMA-targeting
cancer therapy
cancer therapy,BCMA-targeting
cancer therapy,CS1-targeting
cancer therapy,XPO1-targeting
cancer therapy,cereblon-targeting
cancer therapy,proteasome-targeting
cereblon modulator
glucocorticoid
immuno-oncology therapy,BCMA-targeting
immuno-oncology therapy,CS1-targeting
immunomodulatory imide drug
proteasome inhibitor
therapeutic modality,bispecific T-cell engager
therapeutic modality,bispecific antibody
+ XPO1 inhibitor
Multiple myeloma
NSW
2170 - Liverpool - Liverpool Hospital
2217 - Kogarah - St George Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3128 - Box Hill - Box Hill Hospital - Eastern Health
3168 - Clayton - Monash Medical Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
NCT05611931
Advanced
Phase 3
Recruiting
A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma (
XPORT-EC-042
)
XPO1 inhibitor
placebo
Endometrial cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital
2305 - New Lambton Heights - Newcastle Private Hospital
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital
2640 - Albury - Border Medical Oncology Research Unit
VIC
3128 - Box Hill - Box Hill Hospital - Eastern Health
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre
3168 - Clayton - Monash Medical Centre
3199 - Frankston - Peninsula Health Frankston Hospital
3000 - Melbourne - Peter MacCallum Cancer Centre (WITHDRAWN)
QLD
4215 - Southport - ICON Cancer Care
4350 - Toowoomba - Toowoomba Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
NCT04442022
Haem
Phase 2
Recruiting
A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) with or Without Selinexor in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL) (
2020-000605-84--XPORT-DLBCL-030
)
XPO1 inhibitor
anti-CD20 monoclonal antibody
antimetabolite
glucocorticoid
Diffuse large B-cell lymphoma
ACTRN12623000096651
Advanced
Phase 2
Recruiting
LUMOS2
: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS
Cadonilimab
Niraparib
PARP inhibitor
PI3K-delta inhibitor
PI3K alpha inhibitor
PI3K inhibitor
Paxalisib
Selinexor
XPO1 inhibitor
bispecific PD-1/CTLA4 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,PARP-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PI3K-delta-targeting
cancer therapy,PI3K-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,XPO1-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
cancer therapy,mTORC2-targeting
dual PI3K/mTOR inhibitor
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,PD-1-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,PD-1-targeting
mTORC1/mTORC2 inhibitor
mTORC1 inhibitor
mTORC2 inhibitor
mTOR inhibitor
therapeutic modality,bispecific antibody
+ XPO1 inhibitor
Anaplastic astrocytoma
Low-grade glioma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital
2170 - Liverpool - Liverpool Hospital
2298 - Waratah - Calvary Mater Newcastle Medical Oncology
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
TAS
7000 - Hobart - Royal Hobart Hospital
ACTRN12622001366741
Haem
Phase 2
Recruiting
Investigating the efficacy of Risk Directed front-line therapy for Multiple Myeloma incorporating Selinexor: The
RIDDLE-M-X
trial
XPO1 inhibitor
Multiple myeloma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2640 - Albury - Border Medical Oncology Research Unit
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4575 - Birtinya - Sunshine Coast University Hospital
ACTRN12622001313729
Haem
Phase 2
Recruiting
ALLG MM26/D1: Novel Combinations for Orphan Myeloma: The NORM Platform study: Treatment Specific Appendix: Selinexor, Pomalidomide, Dexamethasone (
SPd
)
XPO1 inhibitor
glucocorticoid
immunomodulatory imide drug
Multiple myeloma
ACTRN12621001361897
Haem
Phase 2
Not yet recruiting
A single arm, open-label study of efficacy and safety of the Exportin 1 inhibitor selinexor in relapsed/refractory CNS Lymphoma and in relapsed/refractory CNS Myeloma (
EXCLAIM
)
XPO1 inhibitor
Diffuse large B-cell lymphoma
Multiple myeloma
VIC
3004 - Melbourne, Southbank - Alfred Health
3066 - Epping - Northern Hospital
ACTRN12620000291987
Haem
Phase 3
Recruiting
An ALLG phase 3 randomised trial of Selinexor and Lenalidomide - versus Lenalidomide maintenance post Autologous Stem Cell Transplant for patients with Newly Diagnosed Multiple Myeloma (
SeaLAND
)
XPO1 inhibitor
immunomodulatory imide drug
Multiple myeloma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2139 - Concord - Concord Repatriation General Hospital
2480 - Lismore - Lismore Base Hospital
2640 - Albury - Border Medical Oncology Research Unit
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3004 - Melbourne, Southbank - Alfred Health
3011 - Footscray - Footscray Hospital
3066 - Epping - Northern Hospital
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
3168 - Clayton - Monash Medical Centre
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6150 - Murdoch - Fiona Stanley Hospital
TAS
7000 - Hobart - Royal Hobart Hospital
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (7)
Not yet recruiting (1)
Recruitment Country and State
VIC (6)
NSW (5)
QLD (5)
SA (3)
TAS (3)
WA (2)
Phase
Phase 2 (5)
Phase 3 (3)
Trial Type
Haem (6)
Advanced (2)
Cancer Therapy Class
XPO1
100%
cereblon
50%
proteasome
25%
BCMA
13%
CS1
13%
CD20
13%
CTLA4
13%
PARP
13%
PD-1
13%
PD-1/PD-L1
13%
PI3K-delta
13%
PI3K
13%
PI3Kalpha
13%
mTOR
13%
mTORC1
13%
mTORC2
13%
Facility
3168 - Clayton - Monash Medical Centre (4)
3066 - Epping - Northern Hospital (4)
4102 - Woolloongabba - Princess Alexandra Hospital (3)
2640 - Albury - Border Medical Oncology Research Unit (3)
3000 - Melbourne - Peter MacCallum Cancer Centre (3)
7000 - Hobart - Royal Hobart Hospital (3)
3004 - Melbourne, Southbank - Alfred Health (3)
2170 - Liverpool - Liverpool Hospital (2)
2298 - Waratah - Calvary Mater Newcastle Medical Oncology (2)
3128 - Box Hill - Box Hill Hospital - Eastern Health (2)
2050 - Camperdown - Chris O'Brien Lifehouse (2)
2065 - St Leonards - Northern Sydney Cancer Centre, Royal North Shore Hospital (2)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (2)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (2)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (2)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (2)
2217 - Kogarah - St George Hospital (1)
3065 - Fitzroy - St Vincent's Hospital Melbourne (1)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (1)
2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (1)
2305 - New Lambton Heights - Newcastle Private Hospital (1)
2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (1)
3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
4215 - Southport - ICON Cancer Care (1)
4350 - Toowoomba - Toowoomba Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
4575 - Birtinya - Sunshine Coast University Hospital (1)
2139 - Concord - Concord Repatriation General Hospital (1)
2480 - Lismore - Lismore Base Hospital (1)
2800 - Orange - Orange Hospital-Cancer Centre Clinical Trials Unit (1)
3011 - Footscray - Footscray Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
4814 - Douglas - Townsville Cancer Centre - The Townsville Hospital (1)
6150 - Murdoch - Fiona Stanley Hospital (1)
7250 - Launceston - Launceston General Hospital - Northern Cancer Centre (1)
Cancer Type
Cancer
Haematological malignancy
Multiple myeloma
Plasma cell disorder
Solid tumour
B-cell lymphoma
B-cell malignancy
Diffuse large B-cell lymphoma
High-grade B-cell lymphoma
Lymphoma
Mature B-cell malignancy
Non-Hodgkin's lymphoma
Endometrial cancer
Gynaecological cancer
Anaplastic astrocytoma
Central nervous system cancer
Glioma
High-grade glioma
Low-grade glioma
Malignant glioma
Neurological cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy